Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

TinniMizer

Financiado

Cerrado

TinniMizer A Patient specific Novel Approach for Tinnitus Treatment

Tinnitus can be a debilitating condition, which negatively affects a patient’s overall health and social well-being. Even moderate cases can interfere with the ability to work and socialise. The financial consequences of tinnitus... ver más

31/03/2019

GENMEL TECH

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

GENMEL BIYOMEDIKAL TEKNOLOJI ARGE SANAYI VE T... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-03-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 5 años

0% 70% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

GENMEL TECH

50.00K€ | Lider

FROSST IBERICA

330.43K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 4 meses Fecha Inicio: 2018-11-30
Fecha Fin: 2019-03-31

Líder del proyecto

GENMEL BIYOMEDIKAL TEKNOLOJI ARGE SANAYI VE T... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Tinnitus can be a debilitating condition, which negatively affects a patient’s overall health and social well-being. Even moderate cases can interfere with the ability to work and socialise. The financial consequences of tinnitus are significant. Personal economic loss to an individual with tinnitus--including lost earnings, productivity, and health expenses--can be up to €30,000 annually. The cost to society as a whole has been estimated at upwards of €26 billion annually. Despite these effects there is currently no scientifically proven cure for most cases of chronic tinnitus. The medical doctors (ENT specialists), audiologists, and electronics-biomedical engineers in Genmel Technology have developed a new, patient-specific, state-of-the-art, and patented musical therapy system called TinniMizer as a new treatment for Tinnitus due to a substantial need to cure the tinnitus with an easy-to-use and cost-effective therapeutic system. Preliminary results obtained from about 20 patients at three clinics (Tinnitus Treatment Centers) indicate that after using TinniMizer system for about 3 months, there is approximately 70% reduction in the complaints of tinnitus patients. Through this project, Genmel will further develop this therapy to result in over 95% reduction in tinnitus. In other sound therapy systems, the duration of therapy is 1.5 years. Our goal is to reduce this period to a much shorter period (up to 3 months). Genmel offers R&D solutions, productions, and consulting services especially in the field of Biomedical, Electronics, Medicine and Energy. Academicians, engineers and technicians are working in GENMEL. The main goal of GENMEL is to develop and bring to market new products, services and business models that could drive economic growth. Through this project, Genmel aims to achieve a total turnover of >€14.5 million by the 5th year of TinniMizer commercialization.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores